Abstract: The present invention relates to Saccharomyces boulardii yeast cells, for use in the prevention or treatment of mood disorders, in a person.

Abstract: A pharmaceutical composition for promoting osteoblastogenesis, in particular a yeast cell derived product for use for promoting osteoblastogenesis in an individual. The yeast cell-derived product may be derived from yeast cells of the genus Saccharomyces and from yeast cells of the species Saccharomyces boulardii.

Abstract: The present invention relates to a pharmaceutical oral formulation for use in the administration of at least two bacteria derived from fecal microbiota to mammals for the treatment and/or prevention of dysbiosis and associated pathologies. The pharmaceutical oral formulation is encapsulated mixture of at least two bacteria derived from fecal microbiota wherein the capsules are coated in a pH responsive polymer composition comprising: a. 50-70% poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3:1 by weight of dry polymer, b. 10-30% poly(methacrylic acid-co-ethyl acrylate) 1:1 by weight of dry polymer, c. at least one fatty acid mono-, di- or tri-glyceride ester, or mixtures thereof, d. at least one plasticizer, e. at least one non-ionic emulsifier. The pharmaceutical oral formulation is especially designed to be delivered principally in the ileum and colon and to maintain the sample bacterial viability and diversity.

Abstract: The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of obsessions and/or compulsions in an individual.

Abstract: The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of autism spectrum disorders (ASD).

Abstract: The present invention relates to a dietary supplement or pharmaceutical composition, comprising lyophylized Saccharomyces boulardii as an active ingredient and as sole probiotic, optionally in association with a pharmaceutically acceptable vehicle, wherein the composition is in a closed vial a having a first airtight compartment comprising lyophilized S. boulardii powder, and a second compartment comprising a solution, wherein the first and second compartment can be brought in airtight communication with one another to yield a suspension of S. boulardii to be administered to an individual upon opening of the vial.

Abstract: The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt thereof, to be used in the prevention or treatment of light-induced damage and/or a degeneration of the retina in a patient.

Abstract: The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of peripheral neuropathies.

Abstract: The present invention relates to certain purines, which act as topoisomerase II catalytic inhibitors. These compounds are useful in combination with topoisomerase II poisons, such as anthracyclines and epipodophyllotoxins, in the treatment of proliferative conditions (e.g., cancer). These compounds are useful in the treatment of tissue damage associated with extravasation of a topoisomerase II poison, such as an anthracycline or an epipodophyllotoxin.

Abstract: The present invention relates to a pharmaceutical composition comprising as active substances: at least one compound of the following general formula (I): and at least one inhibitor of type 2 cyclooxygenase (COX-2), notably for use in the prevention or treatment of pain.

Abstract: The present invention relates to a pharmaceutical composition comprising as active substances: at least one compound of the following general formula (I): and at least one compound of the following general formula (V): especially for its use in the prevention or treatment of pain.

Abstract: The present invention relates to the use of at least one compound of formula (I) below: or at least one of the pharmaceutically acceptable salts thereof, for the preparation of a medicament intended for the prevention or for the treatment of cerebral edemas.

Abstract: This invention relates to the use of at least one compound of the following formula (I): or its pharmaceutically acceptable salts, for the preparation of a medicinal compound having neuroprotective activity intended to prevent or treat neurone deteriorations.

Abstract: The invention relates to a method of preparation of fluoroquinolones of formula (I) from compounds of formula (II): in which R1, R2, R3, R4, R5, R6, R7, and X are as defined in Claim 1.

Abstract: The invention relates to the use of L-citrulline (I) or of one of its pharmaceutically acceptable salts in the preparation of a drug for the treatment of states or undernutrition as linked to a lowering of protein synthesis within the framework of pathologies which do not result from an intestinal insufficiency.

Abstract: The present invention relates to a method of treating or preventing weight loss of patients with inflammatory bowel diseases comprising administering to said patients an effective amount of Saccharomyces boulardii.

Abstract: The invention relates to a process for the preparation of stiripentol particles having a defined particle size distribution.

Abstract: The present invention relates to the use of at least one compound of formula (I) below: or of its pharmaceutically acceptable salts, in the preparation of a medicament for the prevention or treatment of cerebral oedemas.

Abstract: The present invention relates to the use of L-citrulline (I) for the preparation of a medicament intended for the treatment of pathologies linked to an intestinal insufficiency.

Abstract: Process for reducing the extent of Cryptosporidium diarrhoeas, which comprises administering to a patient in need thereof a therapeutically effective amount of yeasts of the Saccharomyces boulardii species. The yeasts are freeze-dried living yeasts. The yeasts are provided in the form of unit doses containing 0.050 to 3.0 g of yeasts.